Blue Trust Inc
COLL icon

Blue Trust Inc’s Collegium Pharmaceutical COLL Stock Holding History

Blue Trust Inc’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$23.2K Sell
1,065
-975
-48% -$28.5K ﹤0.01% 1464
2026
Q2 		$73.9K Sell
2,040
-30
-1% -$1.02K ﹤0.01% 1168
2026
Q1 		$68.5K Sell
2,070
-12
-0.6% -$508 ﹤0.01% 1197
2025
Q4 		$96.4K Sell
2,082
-6
-0.3% -$251 ﹤0.01% 1080
2025
Q3 		$73.1K Buy
2,088
+210
+11% +$7.3K ﹤0.01% 1216
2025
Q2 		$55.5K Buy
1,878
+134
+8% +$3.82K ﹤0.01% 1418
2025
Q1 		$52.1K Buy
1,744
+764
+78% +$23.3K ﹤0.01% 1339
2024
Q4 		$28.1K Sell
980
-96
-9% -$3.18K ﹤0.01% 1509
2024
Q3 		$34.6K Buy
1,076
+133
+14% +$4.74K ﹤0.01% 1719
2024
Q2 		$36.6K Buy
943
+122
+15% +$4.23K ﹤0.01% 1394
2024
Q1 		$31.9K Buy
821
+770
+1,510% +$26.9K ﹤0.01% 1072
2023
Q4 		$1K Buy
+51
New +$1.28K ﹤0.01% 2284

Other funds holding COLL

Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return
Royce & Associates
Royce & Associates New York $11B AUM 39.4% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Peregrine Capital Management
Peregrine Capital Management Minneapolis, Minnesota $2.95B AUM 28.43% 1-Year Est. Return
SEI Investments
SEI Investments Oaks, Pennsylvania $113B AUM 26.61% 1-Year Est. Return

Blue Trust Inc's COLL Position: Q3 2026 in Review

Blue Trust Inc reduced its Collegium Pharmaceutical (COLL) stake by 48% in Q3 2026, selling an estimated $28.5K and leaving 1,065 shares worth $23.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1464.

Blue Trust Inc first reported a position in COLL in Q4 2023 and has held it in 12 quarters since. The position peaked at $96.4K in Q4 2025. 118 funds tracked by Wall St. Rank hold COLL as of Q3 2026.

  • Blue Trust Inc held 1,065 shares of Collegium Pharmaceutical worth $23.2K as of Q3 2026.
  • Blue Trust Inc sold 975 Collegium Pharmaceutical shares in Q3 2026, an estimated $28.5K.
  • Collegium Pharmaceutical made up ﹤0.01% of Blue Trust Inc's portfolio in Q3 2026, its #1464 holding.
  • Blue Trust Inc first reported a position in Collegium Pharmaceutical in Q4 2023 and has held it in 12 quarters since.
  • Blue Trust Inc's Collegium Pharmaceutical position peaked at $96.4K in Q4 2025.
  • 118 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q3 2026.

Based on Blue Trust Inc's 13F filing for Q3 2026, filed 15 Oct 2026.